TRVN trevena.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

Trevena, Inc. (TRVN) is establishing strategic partnerships with outpatient centers and hospitals to integrate its developments into clinical practice. The company is creating opioid alternatives, targeting anesthesiologists and US inpatient facilities with its drug Olinvyk. Currently, the business is optimizing resources and focusing on targeted molecular research. This chart of the share price on GURU.Markets shows that the EV/EBITDA is .

Trevena, Inc. specializes in developing innovative analgesics and CNS therapies, which requires significant capital expenditures. The EV/EBITDA metric compares the enterprise value, including net debt, with operating profit, excluding the impact of taxes and depreciation. The current value of allows an investor to assess the fundamental value of assets by analyzing the EV/EBITDA valuation level for signs of being overbought or the risk of default.